Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Prostate Cancer | Current Treatment | Physician Insights | EU5 | 2017

Login to access report north_east
Contact sales account_box

Hormonal therapy is the mainstay of prostate cancer, in all stages of disease and clinical settings. The adoption of novel hormonal agents, Zytiga (Johnson & Johnson/Janssen) and Xtandi (Pfizer/Astellas), for metastatic castrate-resistant disease has driven considerable growth in the size of the prostate cancer market. Penetration of Zytiga and Xtandi (and other novel hormonal agents) in other patient populations (e.g., biochemical recurrent, non-metastatic castrate-resistant disease) will be major market drivers. Other therapies, including Xofigo (Bayer HealthCare) and Jevtana (Sanofi) offer non-hormonal treatment options. However, optimal sequencing of therapies in the crowded castrate resistant prostate cancer armamentarium is still under reconnaissance.

Questions Answered:

  • How does treatment differ, if at all, between biochemically recurrent and non-metastatic castrate resistant prostate cancer patients? What secondary hormone manipulations, if any, are employed?
  • What is the most preferred sequencing of treatment among the asymptomatic, and symptomatic metastatic castrate resistant prostate cancer patients?
  • What are the main key drivers and obstacles to prescribing of the current therapies in the treatment of metastatic castrate-resistant prostate cancer?
  • How does treatment duration of key therapies (e.g., LHRH agonists, Zytiga, and Xtandi) differ by clinical setting (e.g., newly diagnosed patients vs. biochemical recurrent vs. castrate-resistant) according to surveyed physicians?

Markets covered: France, Germany, Italy, Spain, United Kingdom.

Primary research: Survey of 250 European oncologists and urologists (~50 in each of the EU5 countries) fielded in February 2017.

Key companies: Johnson & Johnson, Astellas Pharma (Medivation), Bayer Healthcare, Sanofi-Aventis

Key drugs: Xtandi, Xofigo, Jevtana, Zytiga

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)
Major depressive disorder (MDD) is a widely drug-treated condition managed with multiple drug classes, most commonly selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine…
north_east
Report
Peripheral Arterial Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Peripheral Artery Disease (US)
Peripheral artery disease (PAD) is a subtype of atherosclerotic cardiovascular disease affecting the arteries of the lower extremities and is associated with reduced walking capacity, claudication…
north_east
Report
Psoriatic Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Psoriatic Arthritis (US)
Treatment of psoriatic arthritis (PsA) typically begins with conventional disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, and progresses to more potent biologics and/or…
north_east
Report
Chronic Obstructive Pulmonary Disease – Current Treatment – Current Treatment: Physician Insights – Chronic Obstructive Pulmonary Disease (EU5)
The treatment landscape for chronic obstructive pulmonary disease (COPD) has significantly evolved in the past few years. A plethora of COPD treatments are available in the EU5. These include long-…
north_east
Report
Irritable Bowel Syndrome – Current Treatment – Treatment Algorithms: Claims Data Analysis – IBS-Constipation (including IBS without Diarrhea) (US)
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by altered bowel motility, stool consistency, and frequency, and is classified into constipation-predominant,…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east